LAVA Therapeutics (NASDAQ:LVTX) Short Interest Update

LAVA Therapeutics (NASDAQ:LVTX) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 30,300 shares, a decrease of 50.3% from the January 15th total of 61,000 shares. Based on an average daily trading volume, of 100,500 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.2% of the shares of the stock are short sold.

Hedge Funds Weigh In On LAVA Therapeutics

A hedge fund recently bought a new stake in LAVA Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of LAVA Therapeutics (NASDAQ:LVTX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 19,103 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned 0.08% of LAVA Therapeutics as of its most recent SEC filing.

LAVA Therapeutics Stock Performance

LAVA Therapeutics stock traded up $0.00 during trading on Thursday, hitting $0.94. The company’s stock had a trading volume of 10,535 shares, compared to its average volume of 66,108. The stock’s fifty day moving average is $1.05 and its 200 day moving average is $1.50. LAVA Therapeutics has a 1-year low of $0.85 and a 1-year high of $6.47. The stock has a market capitalization of $24.74 million, a price-to-earnings ratio of -0.91 and a beta of 0.57.

LAVA Therapeutics (NASDAQ:LVTX) last posted its quarterly earnings data on Tuesday, December 10th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.11). On average, research analysts anticipate that LAVA Therapeutics will post -1.13 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on LVTX. Leerink Partners reissued a “market perform” rating and set a $2.00 price target (down previously from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. Leerink Partnrs cut LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. HC Wainwright cut their target price on shares of LAVA Therapeutics from $6.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, December 20th. Citizens Jmp cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Finally, JMP Securities reissued a “market perform” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $3.33.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.